Auxilium Pharmaceuticals, Inc.  

(Public, NASDAQ:AUXL)   Watch this stock  
36.07
+0.21 (0.59%)
After Hours: 36.25 +0.18 (0.50%)
Jan 27, 5:24PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.70 - 36.30
52 week 17.10 - 37.92
Open 35.70
Vol / Avg. 251,604.00/1.29M
Mkt cap 1.83B
P/E     -
Div/yield     -
EPS -3.27
Shares 51.02M
Beta 0.66
Inst. own 131%
Feb 26, 2015
Q4 2014 Auxilium Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 27, 2015
Auxilium Pharmaceuticals Inc Extraordinary Shareholders Meeting
Oct 30, 2014
Q3 2014 Auxilium Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -29.78% -4.51%
Operating margin -21.16% -16.99%
EBITD margin - -3.47%
Return on average assets -11.59% -2.36%
Return on average equity -76.75% -8.00%
Employees 639 -
CDP Score - -

Address

640 LEE ROAD
CHESTERBROOK, PA 19087
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men�s healthcare. The company�s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Officers and directors

Rolf A. Classon Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Adrian Adams President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Andrew Saik Chief Financial Officer
Bio & Compensation  - Reuters
Mark A. Glickman Executive Vice President - Marketing & Sales
Age: 48
Bio & Compensation  - Reuters
Benjamin J. Del Tito Jr., Ph.D. Executive Vice President - Regulatory Affairs and Project Management
Age: 58
Bio & Compensation  - Reuters
Alan J. Wills Executive Vice President - Corporate Development
Age: 50
Bio & Compensation  - Reuters
Jennifer L. Armstrong Senior Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters
Andrew I. Koven Chief Administrative Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Elizabeth Varki Jobes Chief Compliance Officer
Age: 47
Bio & Compensation  - Reuters
James P. Tursi M.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters